Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • spook2b spook2b Jul 8, 2013 5:10 PM Flag

    use of funds (from the prospectus)

    We intend to use the net proceeds from this offering to continue the commercial launch of Vascepa® (icosapent ethyl) capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance our REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes.

    The amounts and timing of these expenditures will depend on a number of factors, such as the success of the commercial launch of Vascepa, whether Vascepa is approved in the ANCHOR indication, the timing, scope, progress and results of our research and development efforts and the timing and progress of any partnering efforts. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds from this offering. Accordingly, we will retain broad discretion over the use of such proceeds.

    Based on our current operating plans, we believe the proceeds from this financing, together with our current cash and cash equivalents, will be sufficient to fund our operations, including the potential need to expand our commercial presence following any approval of Vascepa in the ANCHOR indication, alone or in conjunction with commercial partners, through the end of 2014.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMRN
1.66-0.14(-7.78%)3:59 PMEDT